KAI Pharmaceuticals Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain

admin Portfolio News

South San Francisco, CA — March 31, 2009 — KAI Pharmaceuticals, Inc., a privately  
held drug discovery and development company, today announced the Company has  
initiated a second Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small  
peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC). The study has  
begun enrollment of patients for the treatment of chronic neuropathic pain associated  
with chronic postherpetic neuralgia (PHN). In December 2008, KAI announced the  
initiation of its first Phase 2a study of KAI-1678 in patients with moderate-to-severe  
postoperative pain following total hip or total knee replacement.  
Gregory Bell, KAI’s Senior Vice President of Development and Chief Medical Officer,  
commented, “Our expanded Phase 2 program allows us to study KAI-1678, a promising  
non-opioid, non-NSAID, in multiple indications in both acute and chronic pain. KAI is the  
first company to develop a selective inhibitor of epsilon PKC. We believe there is great  
potential for this novel approach, which may avoid the side effects and limited efficacy of  
currently available treatments.”  
KAI’s Phase 2a PHN study is a double-blind, randomized, placebo- and activecomparator-  
controlled, single-dose, crossover trial designed to evaluate the efficacy of  
KAI-1678 administered by subcutaneous (SQ) infusion. The primary endpoint of the  
study, which is being conducted in Australia, is the mean change from baseline in pain  
intensity scores at the end of drug infusion.  
KAI-1678 has been shown to be highly effective at reversing pain in preclinical models of  
both neuropathic and inflammatory pain, two applications for which epsilon PKC has  
been well-validated in the peer-reviewed scientific literature. The Company’s Phase 1  
results indicated KAI-1678 was safe and well-tolerated in healthy volunteers.  
Background on Pain  
Approximately 50 million people in the United States suffer from some form of persistent  
pain, while another 25 million suffer acute pain each year as a result of injury or surgery.  
It is estimated that 500,000 cases of herpes zoster infection occur in the United States  
each year, and approximately 10 percent of patients with herpes zoster develop  
postherpetic neuralgia.  
Overall, four out of ten people suffering moderate-to-severe pain were unable to find  
adequate pain relief, according to a survey by the American Pain Society. There is a  
major need for novel therapeutics with unique mechanisms of action that provide  
effective pain relief with reduced side effects. Current treatments for pain, such as  
opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), can be limited by serious  
side effects and inadequate efficacy.  
About KAI Pharmaceuticals  
KAI is a drug discovery and development company with multiple, novel clinical-stage  
programs in cardiovascular disease and pain. KAI’s lead product candidate, KAI-9803,  
is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of  
KAI-9803 on reducing myocardial injury in heart attack patients. KAI’s second clinical  
program, KAI-1678, has the potential to address both the inflammatory and neuropathic  
pain markets and currently is in multiple Phase 2a studies.  
KAI’s expertise is in the selective modulation of intracellular protein:protein interactions  
and delivery of peptides into the cell. This approach has broad potential and has been  
validated clinically. The Company has applied its core expertise to discover highly  
potent and selective inhibitors and activators for validated PKC protein kinase C (PKC)  
isozymes. KAI is based in South San Francisco, California, and can be found online at  
CONTACT: KAI Pharmaceuticals, Inc.  
Kristine M. Ball, 650-244-1131  
Chief Financial Officer  
Fax: 650-244-1199  
Burns McClellan, for KAI Pharmaceuticals  
Justin Jackson, 212-213-0006 ext. 327  
Juliane Snowden, 212-213-0006 ext. 343